IBD patients have been found to have a higher risk of lymphoma.

Published Date: 26 Apr 2023

According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.

Read Full News

Latest News

Durvalumab Tied to Extended Biliary Tract Cancer OS Benefit

Researchers examine 4-year outcomes of the phase 3 TOPAZ-1 study.

Low-Volume PEG Wins for Inpatient Bowel Cleansing

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Why the Painless Abdominal Bloating in Middle-Age Man?

Admitted for pyelonephritis, but his diagnostic journey is just beginning

Beware Aspiration Risk in Chronic Pot Users

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Unusual Confluence of Two Rare Syndromes Results in Peculiar Symptoms

Interpretation of an ultrasound exam made all the difference in creating a treatment plan

Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

— Results highlight importance of careful evaluation of concurrent medications, researchers say

Todays Updates

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Todays Updates

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Latest News

Researchers examine 4-year outcomes of the phase 3 TOPAZ-1 study.

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Admitted for pyelonephritis, but his diagnostic journey is just beginning

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Interpretation of an ultrasound exam made all the difference in creating a treatment plan

— Results highlight importance of careful evaluation of concurrent medications, researchers say

News All Time

GLP-1s and Chronic Pancreatitis; Hypoglycemia After Bowel Prep; Lower GI Bleeding

News and commentary from the world of gastroenterology and hepatology

TIPS Was Tops for Refractory Hydrothorax in Cirrhosis

Majority of patients who received TIPS had a complete clinical response

Enhanced MRI Tops Ultrasound in Catching Early Liver Cancer

MRI approach also led to fewer false referrals

Multicancer Early Detection Test Fails to Reduce Cancers Detected at Late Stages

However, an increase in the detection of stage I/II cancers was observed

'A Grand Slam' in Pancreatic Cancer: Novel Pill Doubles Survival

RASolute 302 findings herald a new standard of care in previously treated patients

Albumin 5% Cut Mortality Rates in Sudden Liver Failure With Other Organ Failure

Treatment may be an effective bridge to transplantation for acute-on-chronic liver failure

Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis

More than half of patients saw a biochemical response by 1 year with the novel oral agent

Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival

Non-Operative Treatment for CRC May Include Observation After Complete Response

No difference in disease-free, overall survival compared with 3 years of maintenance therapy

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" expert asks

Large Study Links GLP-1s to Lower Risk of Multiple Cancers

Patients taking the drugs for obesity had a 41% lower risk of related cancers

Fart Frequency in Men vs Women; Organ Transplant in Celiacs; Engineered Gut Bacteria

News and commentary from the world of gastroenterology and hepatology

Study Warns on Sugary Drinks and Liver Cancer

However, no association between artificially sweetened drinks and liver cancer observed

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Roughly one in five patients ditched survodutide due to adverse events

NICU Babies More Likely to Miss Rotavirus Vax

Study shows impact of guidelines' strict upper age limit and suggestion of delay until discharge

Gas-X Recall; MASLD and Alzheimer's Mortality; Counties Without a Gastroenterologist

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

Novel Agent Effective for Cancer Wasting Disorder

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers

Analysis of projected cancer rates in Canada by 2024.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

Charles III, King of Kings, is Cancerous.

Recommended Articles For You

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers 

Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment 

Innovative Pathways in Oncology Across Clinical Settings 

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How AI will transform mental health support for patients with breast cancer

2.

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

3.

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

4.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

5.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

1.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

2.

Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources

3.

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine

4.

Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care

5.

Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

3.

Navigating the Complexities of Ph Negative ALL - Part VIII

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot